Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas

Prat, Ricardo; Galeano, Inma; Lucas, Anna; Martínez, J.; Martín, Maikal Villena; Amador, Román; Reynés, Gaspar

doi:10.1016/j.jocn.2009.02.035

Cited by 55 publications

(43 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, dynamic susceptibility contrast MR imaging showed a substantial false-positive rate, which was not the case with MR spectroscopya finding that points to an incremental value of MR spectroscopy in separating tumor recurrence and posttreatment injury (72).…”

Section: Special Reviewmentioning

confidence: 83%

Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Öz¹,

Alger²,

Barker³

et al. 2014

Radiology

544

368

View full text Add to dashboard Cite

A large body of published work shows that proton (hydrogen 1 [ 1 H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1 H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1 H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1 H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.q RSNA, 2014 Online supplemental material is available for this article. G.O. (e-mail: gulin@cmrr.umn.edu). 2 The complete list of authors and affiliations is at the end of this article.q RSNA, 2014 Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Radiology H MR Spectrum of the Brain: Metabolites and Their Biomarker PotentialMR spectroscopy provides a very different basic "readout" than MR imaging, namely a spectrum rather than an techniques were developed. These early localization techniques included pointresolved spectroscopy (PRESS) (1,2) and stimulated echo acquisition mode (STEAM) (3), methods that are now widely used in clinical MR spectroscopy applications.Preliminary studies revealed large differences in metabolite levels in acute stroke (4), chronic multiple sclerosis (5), and brain tumors compared with healthy brain (6). Although this work stimulated a surge of interest in 1 H MR spectroscopy for diagnosing and assessing CNS disorders during the early days of the "Decade of the Brain" (1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999), many suboptimal patient studies (7) and the lack of consistent guidelines have led to a situation where, 20 years later, MR spectroscopy is still considered an "investigational technique" by some medical professionals and health care organizations. However, the ability to make an early, noninvasive diagnosis or to increase confidence in a suspected diagnosis is highly valued by patients and clinicians alike. As a result, an increasing number of imaging centers are incorporating MR spectroscopy into their clinical protocols for brain...

show abstract

Section: Special Reviewmentioning

confidence: 83%

Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Öz¹,

Alger²,

Barker³

et al. 2014

Radiology

544

368

View full text Add to dashboard Cite

show abstract

“…Only 4 recent studies explicitly reported that patients with high-grade glioma were treated with temozolomide. 33,[38][39][40] Regarding imaging techniques and technologies, included studies generally followed guidelines by the European Association of Nuclear Medicine (On-line Table 3). 42,43 All studies used stand-alone dedicated PET scanners except for 1 study, in which some patients underwent combined PET/CT instead of standalone PET.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…When considering both low-and high-grade gliomas, [16][17][18][19][21][22][23]27,32,33,40,41 sensitivity ranged between 0.23 and 0.95 and specificity ranged between 0.17 and 1.0. For high-grade gliomas, [16][17][18][19]27,34,35,39,41 sensitivity ranged between 0.18 and 1.00 and specificity ranged 0.25 and 1.0.…”

Section: Sensitivity Specificity Likelihood Ratios and Summary Rocmentioning

confidence: 99%

Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis

Nishizaki

Dahabreh

Terasawa

2012

AJNR Am J Neuroradiol

155

105

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE:Studies have assessed PET by using various tracers to diagnose disease recurrence in patients with previously treated glioma; however, the accuracy of these methods, particularly compared with alternative imaging modalities, remains unclear. We conducted a meta-analysis to quantitatively synthesize the diagnostic accuracy of PET and compare it with alternative imaging modalities.

show abstract

“…Furthermore, several authors have shown that perfusion-weighted MRI data are correlated with histological grade [12]. Indeed, perfusion MRI reportedly provides better information or at least the same information as a PET scan, with an excellent correlation between the two techniques [22]. …”

Section: Discussionmentioning

confidence: 99%

Perfusion MRI as a Neurosurgical Tool for Improved Targeting in Stereotactic Tumor Biopsies

Lefranc

Monet²,

Desenclos³

et al. 2012

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Objective: Stereotactic biopsies are subject to sampling errors (essentially due to target selection). The presence of contrast enhancement is not a reliable marker of malignancy. The goal of the present study was to determine whether perfusion-weighted imaging can improve target selection in stereotactic biopsies. Methods: We studied 21 consecutive stereotactic biopsies between June 2009 and March 2010. Perfusion-weighted magnetic resonance imaging (MRI) was integrated into our neuronavigator. Perfusion-weighted imaging was used as an adjunct to conventional MRI data for target determination. Conventional MRI alone was used to determine the trajectory. Results: We found a linear correlation between regional cerebral blood volume (rCBV) and vessel density (number of vessels per mm²; R = 0.64; p < 0.001). Perfusion-weighted imaging facilitated target determination in 11 cases (52.4%), all of which were histopathologically diagnosed as glial tumors. For glial tumors, which presented with contrast enhancement, perfusion-weighted imaging identified a more precisely delimited target in 9 cases, a different target in 1 case, and exactly the same target in 1 other case. In all cases, perfusion-selected sampling provided information on cellular features and tumor grading. rCBV was significantly associated with grading (p < 0.01), endothelial proliferation (p < 0.01), and vessel density (p < 0.01). For lesions with rCBV values ≤1, perfusion-weighted MRI did not help to determine the target but was useful for surgical management. Conclusions: For stereotactic biopsies, targeting based on perfusion-weighted imaging is a feasible method for reducing the sampling error and improving target selection in the histopathological diagnosis of tumors with high rCBVs.

show abstract

Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas

Cited by 55 publications

References 21 publications

Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Clinical Proton MR Spectroscopy in Central Nervous System Disorders

Diagnostic Accuracy of PET for Recurrent Glioma Diagnosis: A Meta-Analysis

Perfusion MRI as a Neurosurgical Tool for Improved Targeting in Stereotactic Tumor Biopsies

Contact Info

Product

Resources

About